The VA has used ambient AI scribes from Abridge and Knowtex in more than 986,000 primary care appointments since October 2025, with veterans opting out less than 1% of the time, and now plans a 2026 enterprise contract to expand the tools nationwide.
The FDA's December 23, 2025 clearance of UpDoc V1.0, the first patient-facing LLM cleared as a medical device, lets a chatbot guide insulin dosing for type 2 diabetes patients at Cleveland Clinic, AHN, and UCSF, but the $18 million-backed startup won't say how much the AI itself shapes the treatment decision.
Yale New Haven Health System and Rad AI announced a June 2026 partnership to deploy AI-assisted radiology reporting across 16-plus outpatient imaging centers and five hospital campuses that together handle more than 700,000 exams annually.
Google and Singapore microbiome firm AMILI launched AMILI Optimise in April 2026, an eight-week AI-driven nutrition program that combines meal photos, continuous glucose monitoring, and fecal sample sequencing to generate personalized dietary recommendations based on gut microbiome data.
A federal court consolidated class actions against Tempus AI on April 15, 2026, alleging the company disclosed patients' genetic data, gathered through its $600 million Ambry Genetics acquisition, to pharmaceutical partners in deals worth $1.1 billion without written consent.
Whoop rolled out AI features called My Memory and Proactive Check-Ins alongside a new fee-based, on-demand video consultation service with licensed clinicians and an EHR-syncing partnership with HealthEx, pushing the wearable maker further from fitness tracking and toward clinical care.
Pennsylvania's State Board of Medicine sued Character.AI on May 1, 2026, alleging a chatbot persona named "Emilie" falsely claimed to be a licensed psychiatrist with a real medical license number, in a first-of-its-kind unlicensed-practice-of-medicine case against an AI companion platform.
Eli Lilly signed a deal worth up to $2.75 billion with Insilico Medicine in March 2026 for a portfolio of preclinical, AI-designed drug candidates, one of the largest AI-pharma partnerships to date, with only $115 million guaranteed upfront.
Hyodol, a ChatGPT-powered companion doll already used by roughly 12,000 elderly South Koreans living alone, registered with the FDA in late 2024 and is targeting a full US launch in 2026 to combat senior isolation and detect falls.
UnitedHealth says its AI-driven PreCheck and OptumReal platforms now approve 96% of prior authorizations on first submission and cut missing-information denials by 68%, even as the AMA and multiple states push back on AI-driven claims denials.